Concerns over the nation’s political stability pre and post-election, the likelihood of no further fiscal stimulus until 2021, signs of a slowing recovery, and a resurgence in the pandemic in many parts of the world have investors in a more bearish mood.
The U.S. pharmaceutical industry is facing a reckoning. Although most pharmaceutical companies have been spared the brunt of the hit suffered by many companies in the wake of Covid-19, back-office inefficiencies have been lurking under the surface for years.
Join the Nasdaq Dorsey Wright (NDW) analyst team to discuss market developments through a technical lens and highlight areas to monitor in the coming weeks.
For many retail investors, dividend yield is incredibly boring. Maybe it is just that in a world where stocks’ percentage gains are often measured in the hundreds, it is hard to get excited about a single digit return.
Federal Reserve Chair Jerome Powell warned that the U.S. economic recovery would suffer without a new fiscal stimulus package. He noted that while the U.S. economy has so far been resilient in the face of the pandemic, that might not last.
Facebook (FB) held its annual Oculus Connect VR conference that was not only rebranded to Facebook Connect, but in keeping with the pandemic, it was a virtual event.
We usually think of the private sector as the leader in innovation. The public sector, on the other hand, has earned a reputation for squabbles and bloated behemoths of programs. As usual, reality is much more complicated than public perception.
Shares of Stitch Fix (SFIX) have rebounded sharply, surging more than 100% since the market bottomed in March, which suggests investors are not as worried about the company’s long-term growth prospects as the share price once indicated.
Richard Saintvilus
Checked
3 minutes 19 seconds ago
This feed is responsible for generating the rss feed related to the topic nasdaq original